InvestorsHub Logo
Followers 137
Posts 3718
Boards Moderated 0
Alias Born 05/10/2006

Re: southswell7 post# 23266

Saturday, 10/03/2020 8:08:39 PM

Saturday, October 03, 2020 8:08:39 PM

Post# of 198700
Do Not 4get this DD for ALL! I have found so much that Todays is enough to Convince ME, the time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!

BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.

Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.

our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680

LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested

BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING

The Company is also looking to expand its Medical Advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. Betting we do NOT have to look far for these Additions.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702

Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294

More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747

https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!

ALSO http://bioclonetics.com/who-we-are.html

Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.

Vice President, Head of Clinical Operations at Epizyme

https://www.linkedin.com/company/epizyme/about/ HUGE!!!

$EPZY NASDAQ $11

Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.

INVESTOR IN BioClonetics!!!

Look up Zoetis!!

Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%), now 163 per share!
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!

1 MORE BIGGIE DD and TIES.

THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS

Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.

Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.

DD HER and Her Company!! Started at Novartis
Pharmaceuticals


https://stcbiologics.com/

STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.

She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.

Here is more from her: https://www.rihl.in/hiv-curable-now-with-monoclonal-antibodies/


This is old, but once again, Shows People knowing People and Companies

Page 19 and 73


https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf

Lastly, old but... you get the point!!

https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!

CHEERS TO THIS MERGER!! GAMECHANGER!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENZC News